Company overview
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing CDNA with another company.
| Daily close (USD) | $62.21 |
| Market capitalization (USD) | $3,218,127,341.71 |
| Price / earnings (TTM) | 28.99 |
| Price / book | 7.56 |
No matching rows. Clear the filter to see all records.
Read CDNA's valuation metrics
Company size
CareDx, Inc.'s recorded market capitalization is $3,218,127,341.71. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
CDNA's recorded P/E is 28.99: about $28.99 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
CDNA's recorded price-to-book ratio is 7.56. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research CareDx, Inc. with Aurora
Use the snapshot above to ask a specific question about CDNA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CDNA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.